P
oliomyelitis is a crippling disease caused by infection with poliovirus. In the 1950s and 1960s, two vaccines were developed to protect people against a severe infection: one inactivated vaccine by Jonas Salk (1) and one live oral polio vaccine by Albert Sabin (2) . These vaccines have since been employed successfully worldwide and decreased the number of cases of paralytic poliomyelitis enormously. The success of vaccines in reducing the incidence of poliomyelitis has made it the next best candidate for full eradication but also has slowed the pace of investment and research to develop antiviral drugs targeting the virus. It has since become clear that eradication is being hampered by the occurrence of vaccine-derived polioviruses and the continuous excretion of the virus by immunocompromised patients (3) . In 2006, the National Research Council of the (U.S.) National Academies reported the necessity of the development of one or more antiviral compounds to help complete the eradication effort and to protect unvaccinated people afterwards (4) .
An important consideration during the development of such an anti-(polio)viral drug is the occurrence of drug resistance of the virus. Poliovirus is a single-stranded RNA virus (5) without any proof-reading activity of its RNA-dependent RNA polymerase (6) . With an error rate of one nucleotide per 10 3 to 10 6 nucleotides copied (7) (8) (9) , poliovirus occurs as a heterogeneous mixture of genomes, also called quasispecies. Challenging the mixed-genome population with an antiviral compound will induce selection of the viruses which possess a certain mutation, allowing the formation of a drug-resistant population. Although they are undesirable in the context of antiviral therapy, these drug-resistant escape mutants are interesting subjects for research and for studying picornaviral capsids (10) . Furthermore, the identification of possible mutants and characterization of their replication and stability features, as well as their resistance to other compounds, are very important given the likelihood of appearing during a treatment with the antiviral, be it in a preclinical or clinical setting.
Due to the amino acid substitutions in these selected mutants, the conformation of the respective protein often is altered (11) . This may, apart from the decreased susceptibility to an antiviral drug, also lead to changes of other aspects of the mutant's phenotype compared to that of the parental virus. Some mutations and their corresponding amino acid substitutions change the binding site of the drug and prevent binding of the compound. Others may change the stability of the capsid; therefore, they also might influence the temperature sensitivity of the virus. Some mutants are unstable to such an extent that binding of the compound is required for a successful infection; therefore, they are called drugdependent mutants (12) .
The recent production and selection of single-domain antibody fragments (variable parts of the heavy chain of a heavy-chain antibody [VHHs] or nanobodies) recognizing and neutralizing poliovirus type 1 (13) offers an interesting new possibility for the development of an antipolioviral drug. VHHs are small and stable proteins (14) derived from heavy-chain antibodies found in camelids (15, 16) , and they recognize and bind their epitopes with high specificity and affinity. Since VHHs are encoded by single genes, they can easily be cloned into specific vectors, enabling large-scale expression in yeast (17) or bacterial (15) expression systems and tailoring of their biological properties. Five of them were reported to neutralize poliovirus type 1 in vitro, with EC 50 s (the concentration of compound where 50% of the cells are viable after infection with virus) in the nanomolar range, and were shown to prevent infection through interference at multiple levels of the infection cycle (18) .
The capsid of poliovirus is formed by the precise positioning of 60 copies of four viral proteins (VP1, VP2, VP3, and VP4) into an icosahedrally symmetric capsid. The surface of the capsid is dominated by star-shaped mesas at the 5-fold axes and three-bladed propeller-like features surrounding the 3-fold axes. These features are punctuated by a deep depression, called the canyon, and by saddle-shaped depressions that span the 2-fold axes. The poliovirus receptor (CD155) has been shown to bind in the canyon (19) (20) (21) (22) (23) . Cryo-electron microscopy analysis of VHH-poliovirus complexes revealed that the binding of these VHHs is also inside the canyon (18; M. Strauss, L. Schotte, B. Thys, D. J. Filman, and J. M. Hogle, unpublished data), and that their binding sites have extensive overlap with the receptor binding site. This overlap contrasts strongly with previously characterized monoclonal antibodies whose binding sites are generally on highly exposed loops with no or little overlap with the receptor binding site.
The overlap of the VHH binding sites with the receptor binding site raises the question of whether the VHHs will be able to select for amino acid substitutions in the virus that will allow the virus to escape neutralization yet maintain the ability to bind receptor, and, if so, where these substitutions would be located. We discuss our findings concerning VHH-resistant escape mutants against the five in vitro neutralizing VHHs, including their selection, identification, and characterization, as well as the screening for cross-resistance against other VHHs.
MATERIALS AND METHODS

Virus and cells.
Monolayers of HeLa cells are cultivated in minimum essential medium containing 5% (vol/vol) bovine calf serum, 100 IU/ml penicillin G, and 100 g/ml streptomycin sulfate (here referred to as cell medium). All incubations of cells at 37°C described throughout the paper were done in the presence of 5% CO 2 . Poliovirus type 1 strain Mahoney was replicated as previously described (24) .
The P1 region of the parental strain used to select VHH-resistant mutants was sequenced and compared to the sequence of Mahoney (NCBI GenBank accession number V01149.1). Six differences were found at the nucleotide level, T1293C, T1391C, G2241A, A2301G, G2400A, and C2419A, resulting in two differences at the protein level, F123S (VP3) and L228I (VP1). The mutations described in Fig. 1 all were compared to the parental strain. Throughout the paper, the Mahoney strain used is the parental strain. Antipolioviral VHHs. Five VHHs were used: PVSP6A, PVSS8A, PVSP19B, PVSS21E, and PVSP29F. They all neutralize poliovirus type 1 in an in vitro setting, with EC 50 s in the nanomolar range. Their selection and production is described extensively in our previous papers (13, 18) .
Pirodavir and 35-1F4. Pirodavir (R77975), ethyl-4-{3-[1-(6-methyl-3-pyridazinyl)-4-piperidiniyl]ethoxy}benzoate, is a research compound synthesized by the Janssen Research Foundation. The compound was provided as a powder and was dissolved in dimethyl sulfoxide (DMSO) to a concentration of 10 mg/ml. Further dilutions were made in cell medium.
35-1F4 is a monoclonal antibody known to bind and neutralize poliovirus type 1 (binds N antigen specifically) (25) . It was previously produced at our department as described in reference 25 and recognizes the N1 antigenic site located at the rim of the 5-fold mesa (26) . Plaque titration. Generally, to perform a plaque titration, virus was serially diluted in Tris buffer (137 mM NaCl, 25 mM Tris, pH 7.2), and 200 l of selected dilutions was placed on a monolayer of HeLa cells in 60-mm petri dishes. The cells and virus were incubated at 37°C for 30 min to allow attachment and were shaken gently multiple times during this incubation period. Five milliliters of an overlay of cell medium containing 1.1% (wt/vol) agar was poured over the cells. After 2 days at 37°C, the cells were fixed using a 10% (wt/vol) formol solution and colored using crystal violet solution (0.2% [wt/vol] Selection of resistant virus. For the selection of resistant virus, first a monolayer of HeLa cells in a 96-well plate was infected with 100 PFU of virus and incubated for 30 min at 37°C. Cell medium containing VHH was added to the cells to obtain a final concentration of 1 nM for PVSP6A or 10 nM for the other VHHs (PVSS8A, PVSP19B, PVSS21E, and PVSP29F). The cells were incubated for 3 days at 37°C or until complete cytopathogenic effect (CPE) was observed. The supernatant was collected and was used to infect fresh cells. The protocol was repeated using increasing concentrations of VHH (0.5 log steps) until a concentration of 1 M VHH was reached.
Plaque purification of neutralization escape mutants. The supernatant obtained after treatment with 1 M VHH was serially diluted (10 Ϫ4 , 10 Ϫ5 , and 10 Ϫ6 ) in cell medium without serum containing 1 M of the respective VHH. Two hundred microliters of the dilutions was placed on a monolayer of HeLa cells in a petri dish, and after 30 min of incubation at 37°C, an overlay of cell medium containing 1.1% agar and 1 M VHH was applied. The cells were incubated for 2 days at 37°C and subsequently stained with 0.1% neutral red for 1 day at 37°C to visualize the plaques. For each VHH, five different plaques were picked, brought into phosphatebuffered saline (PBS) buffer (145 mM NaCl, 50 mM Na 2 HPO 4 · 12H 2 O, pH 7.4), and separately cultivated on HeLa cells in the presence of 1 M the respective VHH to be used in further experiments.
Determination of the mutations and amino acid substitutions. Viral RNA was extracted (RNeasy minikit; Qiagen) from both the plaque-purified mutants and the parental strain and was reverse transcribed to cDNA using RevertAid RT (Thermo Scientific). Double-stranded DNA fragments covering the P1 region of the genome were obtained after PCR using primers 5=-TATCATAAAGCGAATTGGATTGGCC-3= (forward) and 5=-AGGTCTCTACTCCACATGACGTTCACTG-3= (reverse). The P1 region then was sequenced by the VIB Genetic Service Facility (Antwerp, Belgium) using the following forward primers: 5=-CTGTTTGCTG GATCCGCTCC-3=, 5=-TGAGGGACATGGGACTCTTT-3=, 5=-TCACC CTGCCACGCTTACAG-3=, 5=-CGGCAAACCATAGATGATAG-3=, and 5=-GGAGGAAATTGGAGTTCTTC-3=. The sequencing was performed in duplicate. Sequences were analyzed and aligned using Chromas Lite and the CLC Bio Workbench.
Drug dependency. Drug dependency of the mutants was checked by calculating their drug plating index (12) . First, the medium of the mutants was exchanged by VHH-free cell medium without serum using Vivaspin 500 100,000 molecular-weight-cutoff (MWCO) filters (Sartorius). A plaque titration was performed to determine the mutants' titers both in the presence and absence of VHH. The mutants in VHH-free medium were diluted in either Tris buffer or Tris buffer containing 1 M of the respective VHH. An overlay supplemented with 1 M VHH was used for the mutants diluted in Tris buffer with VHH. The drug plating indices of Mahoney also were determined for each of the VHHs. The drug dependency test was performed three times.
Singe-cycle replication curve. Monolayers of HeLa cells in six 96-well plates were infected with either Mahoney or mutant virus in VHH-and serum-free medium (MOI of 10) and incubated at 37°C for 30 min. The inoculum was removed and cells were washed with cell medium without serum. One hundred microliters of cell medium was brought onto the
FIG 1 Mutations and amino acid substitutions of poliovirus type 1 against VHHs. Five neutralization escape mutants against each of five in vitro neutralizing
VHHs were selected, and the P1 genomic region was sequenced. Shown are the mutations found at the genetic level and the substitutions at the protein level. The positions of the nucleotides are those in the open reading frame. One protomer of the capsid is shown, and VP1, VP2, VP3, and VP4 are represented in blue, yellow, red, and green, respectively. The positions of the amino acid substitutions are shown as spheres in cyan (VP1), orange (VP2), magenta (VP3), and gray (VP4). Substitutions were found in all four viral proteins and were located in both accessible (canyon) and nonaccessible regions of the capsid. The images were made in PyMol using PDB entry 1HXS.
cells, and the plates were incubated for 0, 2, 4, 6, 8, or 10 h at 37°C. The cells were frozen at Ϫ80°C and freeze-thawed three times prior to plaque titration of the samples (in the absence of VHH). Stability of the resistant phenotype in the absence of VHH. Monolayers of HeLa cells (4 ϫ 10 4 cells) were infected with 100 PFU of mutant virus and incubated for 30 min at 37°C. Cell medium was added, and the cells were incubated at 37°C until complete CPE was seen. The supernatant was diluted (8,000ϫ) and used to infect a new monolayer of HeLa cells. This process was repeated until the mutants were passaged 10 times in cells in the absence of VHH. The EC 50 s of both the original and the passaged mutant then were determined. A level of 100 PFU was used to infect a monolayer of HeLa cells (4 ϫ 10 4 cells) at 37°C for 30 min. Fourfold (for PVSP6A) or threefold (for the other VHHs) dilutions of the VHHs in cell medium then were added to the cells, and the samples were incubated at 37°C for 3 days or until complete CPE was observed in control wells. The cell viability was measured using Cell Titer Blue (Promega). The EC 50 s were determined at least three times for each mutant and Mahoney.
Thermal stability of the mutants. Samples of mutants and Mahoney (4.2 ϫ 10 7 Ϯ 0.57 ϫ 10 7 PFU/ml) in cell medium without VHH and serum were heated at 44°C for 0, 7.5, 15, 30, or 60 min and cooled on ice immediately after heating. A plaque titration was performed to determine the titer of each sample. The test was done three times.
Cross-resistance. To determine cross-resistance, first 100 PFU of the escape mutants was used to infect a monolayer of HeLa cells (4 ϫ 10 4 cells). The cells were incubated for 30 min at 37°C, and cell medium containing either neutralizing VHH (1 M final concentration), monoclonal antibody 35-1F4, or pirodavir (27 M final concentration) was added. Pirodavir was diluted in two steps. In the first step, pirodavir was diluted in cell medium to obtain less than half of the saturating concentration. The second dilution step resulted in the working concentration of pirodavir, plus 0.125% (vol/vol) DMSO. After a 3-day incubation at 37°C or after CPE was observed for the respective control cells, cell viability was measured using Cell Titer Blue (Promega) and the percentage of cell viability was calculated. This cross-resistance test was repeated four times.
To determine whether the virus that replicated in these cross-resistance experiments still maintained its resistance against the original selector VHH, we used 100 PFU of the virus in the supernatant of the crossresistance experiment to infect a monolayer of HeLa cells (37°C for 30 min). Cell medium containing the VHH to which the mutant originally raised resistance then was added. After 3 days, or when complete CPE was observed in the control wells, cell viability was measured using Cell Titer Blue (Promega).
RESULTS
Selection and identification of the mutants.
Neutralization escape mutants were selected against each of the five in vitro neutralizing VHHs by treating poliovirus type 1 Mahoney with gradually increasing concentrations of VHH (1 M maximal concentration). For each of the VHHs, five different plaques were picked, and the P1 region of the plaque-purified mutants was sequenced. An overview of the mutations and amino acid substitutions is given in Fig. 1 . From the five variants selected, four different variant types were seen for PVSP6A and PVSS21E and three for PVSP19B, while only two different variants were detected for PVSS8A and PVSP29F. All four viral proteins of the capsid are subject to change caused by mutation. However, it can be noted that the amino acid substitutions are localized most frequently in VP1 (31/41 substitutions) and VP2 (8/41), while the amino acids in VP3 and VP4 were substituted just once each. There are 17 different amino acid substitutions, of which 12 are in VP1, three in VP2, and one in VP3 and VP4.
The positions of the amino acid substitutions on the capsid are shown in Fig. 1 . Some substitutions are found to be in nonaccessible regions of the capsid (either buried in subunit interfaces or on the inner surface of the capsid), while others are seen in surface-exposed regions surrounding the canyon in residues at the periphery of the receptor-binding site. The mutants 8A_1, 8A_2, 8A_3, 8A_5, and 21E_5 are resistant to their respective VHH just by having one amino acid substitution located in the region at the interface between VP2 and VP3. Both the position of the exposed, substituted amino acids at the periphery of the binding site and the prevalence of substitutions at surface-inaccessible residues is in sharp contrast to the observations with neutralizing monoclonal antibodies, which generally selected substitutions only in highly exposed loops. For antibodies where Fab-virus complexes are known, these exposed loops are in the center of the binding site.
Most of the escape mutants (15 out of 25) have a double-amino-acid substitution. Eight variants have a single amino acid that is replaced, and mutant 29F_5 has three substitutions. In variant 8A_4, no mutations that lead to amino acid substitutions were found, with only three silent mutations. It is unclear thus far how this variant can show resistance to PVSS8A. This variant could not be replicated for further characterization; therefore, it was not included in the other experiments in this paper. All of the other variants, including 6A_1, 6A_2, 6A_3, 6A_4, 8A_1, 19B_1, 19B_2, 19B_3, 21E_1, 21E_2, 21E_3, 21E_5, 29F_1, and 29F_5, were characterized further.
Drug dependency. To determine whether the mutants were depending on the presence of the VHHs to induce a successful infection, the titers of the mutants were defined in both the absence and presence of their respective VHH. This allows the calculation of their drug plating index, which is the ratio between the titer in the presence of the drug and the titer in the absence of the drug ( Table 1 ). All of the indices are found to be between 0.23 and 1.7 for the mutants and to be under 0.0048 for Mahoney.
Single-cycle replication curve. The replication characteristics of the mutants were studied in a single-cycle replication experiment. In Fig. 2 the replication curves are shown. All of the mutants seem to have replication characteristics that are very similar to those of their parental strain. The titers of mutant virus obtained 10 h after infection all were comparable to the titer reached for their parental strain (mean titer after 10 h was 4.6 ϫ 10 8 Ϯ 0.5 ϫ 10 8 PFU/ml). The replication kinetics also follow the same pattern. The only minor deviations are the titers measured after 4 h of incubation for mutants 6A_1 and 19B_1, which seem to be one log higher than the titer obtained for Mahoney at this point. However, at the other incubation times, the titers obtained for these mutants and Mahoney are very similar.
Stability of the resistant phenotype in the absence of VHH. The mutants were passaged in HeLa cells in the absence of compound to assess the stability of their resistance phenotype. After 10 passages, the EC 50 s of both the original (passage 0 [P0]) and the passaged (P10) mutant were determined (Fig. 3) in a multicycle cytopathic reduction assay. The geometric mean EC 50 s demonstrate that, before the passage over cells in the absence of the VHH, the mutants had a susceptibility that was reduced between 32.5-fold (21E_5) and Ͼ6,014-fold (6A mutants) compared to that of Mahoney. It also can be seen (Fig. 3) that the mutations are sufficiently stable to prevent reversion to their initial VHH-susceptible state. However, four mutants, 6A_1, 6A_2, 19B_3, and 21E_5, did show an increase in susceptibility to the VHHs, indicated by a decrease in their EC 50 s.
Thermal stability. The thermal stability of the mutants was tested by heating of viral samples to 44°C. These experiments were done because our previous paper investigating the mechanism of neutralization showed that all five VHHs interfered with the uncoating of the virus and stabilized the capsid (18) . As represented in Fig. 4 , all of the mutants showed very good resistance against heat inactivation. The titer at time 0 min was 4.2 ϫ 10 7 Ϯ 0.57 ϫ 10 7 PFU/ml, and there were no significant (␣ ϭ 0.05) differences between the titers of the mutants and Mahoney at time zero (data not shown). After heating the virus samples at 44°C, the fraction of infectivity remaining seemed to be higher for most of the mutants than for Mahoney when looking at the graphs in Fig. 4 . However, when using an unpaired t test to calculate the differences between the fractions of infectivity remaining after heating the virus for 60 min at 44°C (Fig. 4) , only mutants 6A_4, 8A_1, and 19B_2 were shown to be significantly more stable than Mahoney in terms of thermal inactivation at 44°C.
Cross-resistance. To determine whether a mutant resistant to one VHH also shows resistance to other VHHs, we infected cells with a mutant and treated the cells with either a VHH different from the one against which original resistance was established, with the antiviral compound pirodavir, or with the poliovirus neutralizing antibody 35-1F4. The results of the mutants tested are represented in Fig. 5 . In these graphs, the percentage of cell viability measured in the well after infection of the cells with the indicated mutant and treatment with the VHH or compound (shown on the x axis) is given. This percentage was calculated using the following formula: (signal of sample minus signal of 0% control) divided by (signal of 100% control minus signal of 0% control) times 100, where the 0% control is a control where cells were infected but not treated and the 100% control is a control in which cells were neither infected nor treated.
As a first observation, we see that cross-resistance does occur for most of the variants, except for 6A_1, 6A_4, 21E_1, and both 29F_1 and 29F_5, which still are susceptible to neutralization by the four other VHHs. In contrast, all of the tested mutants still could be fully neutralized by at least two other VHHs at a concentration of 1 M, e.g., the cells infected with variant 8A_1 and treated with VHH PVSP6A or PVSP19B retain full viability after 3 days of incubation at 37°C. Although most of the mutants showed cross-resistance to other VHHs, none of the amino acid substitutions interfered with the binding and neutralizing activity of the antiviral compound pirodavir (except for 19B_1) or the monoclonal antibody 35-1F4.
When looking at the mutants resistant to PVSP6A, 6A_1 and 6A_4 do not show cross-resistance to other VHHs. 6A_2 and 6A_3 are no longer susceptible to neutralization by PVSS8A and PVSS21E, probably due to the VP2 H142R and VP1 V61M substitutions also found in 21E_2 and 21E_3, respectively. In the case of 6A_2, the resistance to neutralization by PVSS8A also could be due to the VP1 V47L substitution. 6A_4 also contains the VP2 H142R substitution, but the VP3 D209V substitution might compensate for this and allow neutralization by PVSS21E.
The mutants against PVSS8A have a single, dominant substitution (VP1 V47L) that induces cross-resistance against PVSS21E and PVSP29F.
The mutants against PVSP19B all are resistant to PVSS21E. Interestingly, mutants 19B_1 and 19B_3 only differ in the replacement of glutamic acid at position 168 of VP1 by either glycine or lysine, respectively. This seems to influence the cross-resistance pattern, as 19B_1 shows resistance against pirodavir and 19B_3 does not. In contrast, 19B_3 is resistant to neutralization by PVSS8A and 19B_1 is not. The glutamic acid-to-glycine substitution somehow influences the binding of pirodavir to 19B_1, while replacement of this same glutamic acid by lysine does not interfere with neutralization by pirodavir in 19B_3 but does disturb neutralization by PVSS8A.
Of the five selected variants resistant to PVSS21E, four have only a single substitution, of which one, in 21E_5, is located on VP4. 21E_1 (VP2 T139I) still can be neutralized by the other four VHHs, while an extra substitution (VP1 V61M) introduces resistance to PVSS8A and PVSP19B.
The mutants against PVSP29F have a rather limited variation in their amino acid substitutions, and these are not shared by any of the variants resistant to the other VHHs. They specifically introduce resistance to PVSP29F and do not seem to interfere with the binding of and neutralization by the other VHHs, pirodavir, or the monoclonal antibody 35-1F4.
Considering the frequency of development of cross-resistance against a certain VHH, PVSP6A is the best in class, with only one mutant out of 10 selected by the other VHHs being cross-resistant against PVSP6A. PVSS21E is the weakest, since 60% of the mutants that were selected by other VHHs and that were tested for cross-resistance against PVSS21E were positive. PVSP29F (17%), PVSP19B (18%), and PVSS8A (46%) have percentages between these two extremes.
Given the similar binding sites of the different VHHs, we were concerned that the presence of the original selecting VHH could interfere with the binding of other VHHs in the cross-neutraliza- The final concentration of VHH in the samples and the overlay was 1 M. This corresponds to 6.02 ϫ 10 14 VHHs per ml or 13.8 g/ml of PVSP6A, 14.6 g/ml of PVSS8A, 14.0 g/ml of PVSP19B, 13.9 g/ml of PVSS21E, or 14.4 g/ml of PVSP29F. tion experiments. Thus, the cross-resistance test was done in the absence of the first selector VHH. To test whether the variant virus, which formed in the wells where cross-resistance was seen, was still the original mutant and not a newly selected genotype, these variant multiresistant viruses were tested once more against the original VHH. The percentages of viable cells infected with the multiresistant virus and treated with its original VHH are shown in Fig. 6 . For example, 6A_2/8A is the virus that replicated in the well infected with 6A_2 and treated with VHH PVSS8A. As controls, the mutant virus from the same cross-resistance experiment and treated with its original selector VHH (e.g., 6A_2/6A) also was measured in this experiment. No significant difference (␣ ϭ 0.05) was seen between any of the variants which replicated in the absence of the original selector VHH compared to the one which replicated in the presence of the same VHH.
DISCUSSION
Genotypes of the neutralization escape mutants. The sequencing of the P1 genome region of five plaque-purified neutralization escape variants of poliovirus type 1 for each of five in vitro neutralizing VHHs (PVSP6A, PVSS8A, PVSP19B, PVSS21E, and PVSP29F) lead to some interesting observations. First, amino acid substitutions in all four of the viral proteins were found. Even though most of the substitutions are located near the binding sites of the VHHs on the virion (which was shown to be the canyon), six different substitutions (VP1 A43T, VP1 V47L, VP1 V61M, VP2 A121T, VP3 D209V, and VP4 I62T) were found to be located in regions of the capsid that are further away from the canyon and are more internal in the capsid. The VP1 V47L and VP4 I62T substitutions even occur as single-amino-acid substitutions; thus, they are fully responsible for the resistant phenotype of variants 8A_1 and 21E_5, respectively. Mutants resistant to conventional antibodies tend to mutate in epitopes that are more exposed on the surface of the capsid, e.g., in the loop regions at the 5-fold axis of symmetry (BC and EF loops of VP1) or the loops surrounding the canyon (EF loop of VP2 and GH loop of VP1) (27) (28) (29) (30) (31) (32) (33) (34) (35) . The dimensions of conventional antibodies (approximately 10 times those of VHHs) usually allow them to recognize only these epitopes on the capsid that are easily accessible; therefore, escape mutations are clustered in defined regions that are consistent with the area of the antigen binding site at the tip of each Fab. In contrast, the amino acid substitutions selected by the VHHs that are in exposed residues are at the periphery of the footprint of the VHH rather than in the center of the site. Note that the GH loop of VP1 and the EF loop of VP2 are within the VHH footprint but also are highly exposed components that belong to major antigenic sites; therefore, they are the locations of escape substitutions from both conventional antibodies and VHHs. The conformation and dimensions of VHHs make it advantageous for them to interact inside the canyon in order to maximize the contact area between the VHH and the virus. Since the binding sites of the VHHs and that of the natural poliovirus receptor (CD155) (18 and Strauss et al., unpublished) are so similar, the virus now is more limited in the residues it can mutate without affecting its infectivity. Thus, changing the residues at the center of the VHHs' binding sites also ; n Ն 3) and EC 50 geometric means are summarized in the table insets. It is seen that none of the mutants regained full susceptibility to the VHH. pEC 50 is the negative log of the EC 50 value (in M). NM, not measured.
would be likely to have a deleterious effect on receptor binding. The occurrence of amino acid substitutions in internal and nonaccessible regions of the capsid also contrasts with the almost exclusive surface localization of escape mutations selected by monoclonal antibodies. It should be noted, however, that the presence of amino acid substitutions outside the immediate binding site is not unique to the VHHs. Thus, Blondel and colleagues have shown previously that mutations affecting neutralization by antibodies recognizing the N2 antigenic site can be located both outside and inside the binding site (36) and must act by a mechanism other than simple steric interference with antibody binding. In our data, some substitutions (VP1 A43T, VP1 V47L, VP1 V61M, and VP4 I62T) are located remarkably far from the binding site on the inner surface of the virion, and several others, which may map closer to the VHH binding site (including VP1 A150V, VP2 A121T, and VP3 D209V), are in residues in intersubunit interfaces that are not exposed on the surface; therefore, they also are unlikely to seriously impact binding of the VHHs to the capsid. This type of mutation seems to be sufficient to permit resistance against the VHHs with the lowest poliovirus neutralizing capacity (and highest EC 50 s: PVSS8A and PVSS21E). For the other three VHHs, which have lower EC 50 s, the substitution of surface-exposed residues at the periphery of the binding site seems to be essential to escape neutralization. Although most of these amino acid substitutions are in very close proximity to the VHH binding site and may actually directly contact the selective VHH (18 and Strauss et al., unpublished), we argue that the location at the periphery of the binding site would be expected to produce at most marginal effects on VHH binding affinity. Interestingly, in every case the substitutions occur in residues where the structure of the particle is known to change upon the receptor-induced conformational changes associated with cell entry. Based on the observation that in all cases binding VHHs stabilizes the virion and that most of the VHHs neutralize at copy levels below those required to prevent receptor binding, we have previously argued that the VHHs neutralize virions by preventing conformational changes required for cell entry (18) . Taken together, the data presented here suggest that both the internal and surface amino acid substitutions confer resistance to the VHHs, at least in part by interfering with the ability of the VHH to prevent conformational changes needed for cell entry.
It is interesting that when primate antibodies were identified that cross-neutralize both poliovirus serotypes 1 and 2 (thereby avoiding the usual highly exposed antigenic sites), the antibody binding sites overlapped that of the receptor, and the escape substitutions included residues 65, 109, and 166 of VP1 (37, 38) . These findings clearly are very similar to our results using neutralizing VHHs and suggest that the mechanisms of neutralization are similar.
Characteristics of the selected mutants. When testing antiviral compounds, the possibility of developing therapy-resistant variants should always be considered, and knowledge of the implications of these resistant variants is very important. The singlecycle replication kinetics of the mutants are very similar to those of their parental Mahoney strain. This shows that the amino acid substitutions found in the variants offer little advantage or disadvantage for the variants, and that the variants will replicate to the same extent as the parental strain in the absence of the VHH. This also has been observed for other neutralization escape variants against poliovirus types 1, 2, and 3 (39, 40) .
Previously, a number of mutations in poliovirus type 2 (40) and type 3 (12) , selected for resistance to neutralization by an antiviral drug, were found to be dependent on the drug against which resistance was developed. They were called drug-dependent variants. The similarity between the single-cycle replication curves of Mahoney and the mutants in the absence of compound pro- The test was performed four times, and the data are shown as mean values Ϯ SEM. The percentages of cell viability after infection with the mutants and treatment with a certain compound were compared to the corresponding percentages for Mahoney in one-way ANOVA tests using a Dunnett's post hoc test (*, P Յ 0.05; **, P Յ 0.01; ***, P Յ 0.001). Cross-resistance is observed for most of the mutants, but all of the mutants still could be neutralized by at least two other VHHs, pirodavir (except for 19B_1) and 35-1F4. vides evidence that none of the variants depends on the presence of its corresponding VHH in order to induce infection. However, this is not conclusive, as a drug-dependent mutant against poliovirus type 3 showed similar single-cycle replication characteristics in the presence and absence of a drug (12) due to problems at the level of virus release from the cells in the absence of compound. A more specific method to determine drug dependency is to calculate the drug plating index (DPI). This is the ratio between the titers of the variant measured in the presence and the absence of the drug. Variants with a DPI between 0.001 and 0.01 (40) are only slightly resistant to the drug, those with a DPI of around 1 are not dependent on the drug for infectivity, and those with a DPI of 100 or higher are drug dependent. Therefore, all of the variants characterized in this study have DPIs between 0.23 (21E_5) and 1.7 (8A_1) and have no amino acid substitutions that destabilize the capsid to such an extent that the VHH is essential for infection. The DPIs of the wild-type Mahoney strain all are under 0.0048.
We have shown that binding of the VHHs stabilizes the virions against heat degradation (18) . Therefore, we hypothesized that the VHH-resistant escape substitutions would be destabilizing, thereby counterbalancing the effect of the VHHs. On the contrary, all of the tested variants were at least as stable against heat inactivation as the parental strain, and most of them appeared to be even more stable at 44°C. The test was performed three times for each variant, but due to rather large variations, the difference was significant (P Ͻ 0.05) for only three variants (6A_4, 8A_1, and 19B_2). Therefore, it would be very interesting to repeat this test with variants where single mutations were introduced into the P1 region. That would make clear which amino acid substitutions are responsible for this extra stabilization against heat, which could be useful in vaccine production. The mechanism of stabilization of these substitutions is rather puzzling. Possibly, the amino acid substitution(s) present in the variants introduces a decrease in the flexibility of the loops, making the capsid more resistant to heat destabilization, or the substitutions may make the release of the pocket factor from the pocket more difficult, which has been shown to be a necessary step in receptor binding (22) . As a third possibility, the substitutions might influence a structure involved in externalization of the viral RNA from its capsid. The three internal VP1 mutations (VP1 A43T, VP1 V47L, and VP1 V61M) all belong to the same (relatively short) section of the N-terminal extension of VP1, where it wraps under the inner surface of the VP3 beta barrel. Since all of the amino acid substitutions are stabilizing, it can be suggested that their effect is to prevent the Nterminal extension of VP1 from being externalized during capsid expansion. Consistent with this idea, the VP4 mutation belongs to a part of the VP4 carboxyl end that holds the VP1 segment in place beneath the VP3 barrel.
Mutants often revert to their original phenotype. Usually, mutants with a single mutation revert by the introduction of a second amino acid change that restores the parental phenotype. These single-mutation variants also are more likely to revert compared to the more stable variants with multiple mutations (11) . Fifteen of the 25 selected mutants have a double-amino-acid substitution. The stability of the resistant phenotypes of all of the variants was analyzed by determining their EC 50 s before and after the passage (10 rounds) in HeLa cells in the absence of the VHH. The data show that even the mutants with a single-amino-acid substitution do not regain their original susceptibility to the VHHs. 21E_5 (VP4 I62T) is the variant with the least persistent resistance phenotype and is only nine times less susceptible to PVSS21E than its parental strain after 10 passages without VHH. Therefore, this variant is expected to revert spontaneously when circulating in the absence of VHH. The other single-amino-acid substitutions in 8A_1, 21E_1, and 21E_2 offer more stable resistance phenotypes, as these variants showed no measurable decrease in EC 50 after the passages. Given their similar replication kinetics and slightly increased thermal stability compared to those of Mahoney, the mutants might continue replicating next to its parental strain in the absence of VHH. In this context, it is very important to investigate their susceptibility to other VHHs, antiviral compounds, or antibodies. As seen in cross-resistance experiments, the resistant variants all still are susceptible to neutralization by at least two other VHHs (five of them even retain susceptibility to all of the other VHHs), to pirodavir (except for 19B_1), and to 35-1F4. Combining two or more VHHs into a VHH construct, or simply combining them as single VHHs in therapy, may be interesting.
As an important continuation of these data, it would be valuable to examine whether the selected mutants are of any clinical significance by checking their neurovirulence in in vivo models. Also, reverse genetics experiments inducing all single-amino-acid substitutions into the capsid region may provide additional insights into the precise mutations and corresponding amino acid substitutions inducing resistance against the VHHs and increased temperature stability.
Conclusion. The data presented in the manuscript show that neutralization escape mutants of poliovirus type 1 can be selected against each of the five in vitro neutralizing VHHs tested. Sequencing of the P1 region of the poliovirus genome showed that the variants have amino acid substitutions in all four of the viral proteins of the capsid and that they are located both at the edge of the binding sites of the VHHs and also on sites further away from the canyon and hidden beneath the surface. Although the substitution of residues at the edge of the VHH binding site could reduce the binding affinity of the VHH, we predict this effect would be minimal. Interestingly, all of the substitutions, including those at the surface and those that are buried, occur in residues in areas of the structure that undergo receptor-induced conformational changes during cell entry. If the amino acid substitutions (either surface or buried) render these regions more prone to change, the ability of the mutants to escape neutralization could be due at least in part to interfering with the ability of the VHH to inhibit the structural changes necessary for infection. Characterization of the mutants made clear that they have single-cycle replication kinetics similar to those of their parental strain and that they all are drug independent. Their resistant phenotypes are stable, as they do not regain full susceptibility to the VHH after 10 rounds of passage in HeLa cells in the absence of VHH. They are all at least as stable as the parental strain against heat inactivation at 44°C, and three of them are even significantly (P Ͻ 0.05) more resistant to inactivation by heat. The resistant variants all can still be neutralized by at least two other VHHs, and all but one retain full susceptibility to pirodavir and 35-1F4.
